Cargando…

Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report

Vancomycin is a glycopeptide antibiotic used for prophylaxis and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Although major organ sizes and functions mature during infancy, pharmacokinetic studies, especially those focused on infants, are limited. Changes in extrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraishi, Chihiro, Kato, Hideo, Imai, Hiroshi, Iwamoto, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915104/
https://www.ncbi.nlm.nih.gov/pubmed/36767208
http://dx.doi.org/10.3390/ijerph20031839
_version_ 1784885823301222400
author Shiraishi, Chihiro
Kato, Hideo
Imai, Hiroshi
Iwamoto, Takuya
author_facet Shiraishi, Chihiro
Kato, Hideo
Imai, Hiroshi
Iwamoto, Takuya
author_sort Shiraishi, Chihiro
collection PubMed
description Vancomycin is a glycopeptide antibiotic used for prophylaxis and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Although major organ sizes and functions mature during infancy, pharmacokinetic studies, especially those focused on infants, are limited. Changes in extracorporeal membrane oxygenation-related drug disposition largely contribute to changes in pharmacokinetics. Here, pharmacokinetic profiles of vancomycin in an infant receiving extracorporeal membrane oxygenation therapy are presented. A two-month-old Japanese infant with moderately decreased renal function was started on 12.0 mg/kg vancomycin every 8 h from day X for prophylaxis of pneumonia during extracorporeal membrane oxygenation therapy. As the trough concentration of vancomycin observed on day X+3 was 27.1 μg/mL, vancomycin was then discontinued. The trough concentration decreased to 18.6 μg/mL 24 h after discontinuation, and 9.0 mg/kg vancomycin every 12 h was restarted from day X+5. On day X+6, the trough concentration increased to 36.1 μg/mL, and vancomycin therapy was again discontinued. On day X+7, the trough concentration decreased to 22.4 μg/mL. The pharmacokinetic profiles of vancomycin based on first-order conditional estimation in this infant were as follows: plasma clearance = 0.053 L/kg/hour, distribution volume = 2.19 L/kg, and half-life = 29.5 h. This research reported the prolonged half-life of vancomycin during extracorporeal membrane oxygenation in infants with moderately decreased renal function.
format Online
Article
Text
id pubmed-9915104
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99151042023-02-11 Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report Shiraishi, Chihiro Kato, Hideo Imai, Hiroshi Iwamoto, Takuya Int J Environ Res Public Health Case Report Vancomycin is a glycopeptide antibiotic used for prophylaxis and treatment of infections caused by methicillin-resistant Staphylococcus aureus. Although major organ sizes and functions mature during infancy, pharmacokinetic studies, especially those focused on infants, are limited. Changes in extracorporeal membrane oxygenation-related drug disposition largely contribute to changes in pharmacokinetics. Here, pharmacokinetic profiles of vancomycin in an infant receiving extracorporeal membrane oxygenation therapy are presented. A two-month-old Japanese infant with moderately decreased renal function was started on 12.0 mg/kg vancomycin every 8 h from day X for prophylaxis of pneumonia during extracorporeal membrane oxygenation therapy. As the trough concentration of vancomycin observed on day X+3 was 27.1 μg/mL, vancomycin was then discontinued. The trough concentration decreased to 18.6 μg/mL 24 h after discontinuation, and 9.0 mg/kg vancomycin every 12 h was restarted from day X+5. On day X+6, the trough concentration increased to 36.1 μg/mL, and vancomycin therapy was again discontinued. On day X+7, the trough concentration decreased to 22.4 μg/mL. The pharmacokinetic profiles of vancomycin based on first-order conditional estimation in this infant were as follows: plasma clearance = 0.053 L/kg/hour, distribution volume = 2.19 L/kg, and half-life = 29.5 h. This research reported the prolonged half-life of vancomycin during extracorporeal membrane oxygenation in infants with moderately decreased renal function. MDPI 2023-01-19 /pmc/articles/PMC9915104/ /pubmed/36767208 http://dx.doi.org/10.3390/ijerph20031839 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Shiraishi, Chihiro
Kato, Hideo
Imai, Hiroshi
Iwamoto, Takuya
Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
title Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
title_full Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
title_fullStr Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
title_full_unstemmed Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
title_short Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
title_sort impact of extracorporeal membrane oxygenation in an infant treated with vancomycin: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915104/
https://www.ncbi.nlm.nih.gov/pubmed/36767208
http://dx.doi.org/10.3390/ijerph20031839
work_keys_str_mv AT shiraishichihiro impactofextracorporealmembraneoxygenationinaninfanttreatedwithvancomycinacasereport
AT katohideo impactofextracorporealmembraneoxygenationinaninfanttreatedwithvancomycinacasereport
AT imaihiroshi impactofextracorporealmembraneoxygenationinaninfanttreatedwithvancomycinacasereport
AT iwamototakuya impactofextracorporealmembraneoxygenationinaninfanttreatedwithvancomycinacasereport